invest1 publisher
An FDA hold reaches opacalim before SK Biopharmaceuticals pays the $350 million at closing
Kiwoom Securities says the FDA has suspended new enrollment in one of two registrational trials of the epilepsy drug SK Biopharmaceuticals agreed to license from Biohaven last month, and the closing payment is still outstanding.
Publishers:en.sedaily.com
Reality
- Evidence45
- Adoption35
- Hype gap+10
- Incentives65
- Confidence50